share_log

8-K: Current report

8-K: Current report

8-K：重大事件
美股SEC公告 ·  11/20 06:01

Moomoo AI 已提取核心信息

Conduit Pharmaceuticals Inc. announced significant corporate changes in a recent Form 8-K filing with the SEC. On November 14, 2024, Simon Fry was appointed as a director of the company, effective December 18, 2024, after the annual meeting of stockholders. Fry brings over 35 years of investment banking experience to his new roles on the Audit and Compensation Committees. His initial compensation includes a stock option to purchase 420,000 shares of common stock. Additionally, on November 15, 2024, an amended employment agreement was executed with James Bligh, who will continue as the Interim Chief Financial Officer and Senior Vice President – Strategy. Bligh's agreement includes a £400,000 annual salary and up to a 40% discretionary cash bonus. The company also adopted an amendment to its bylaws, effective post the 2024 annual meeting, changing the quorum requirement for stockholder meetings from a majority to at least one-third of the voting power.
Conduit Pharmaceuticals Inc. announced significant corporate changes in a recent Form 8-K filing with the SEC. On November 14, 2024, Simon Fry was appointed as a director of the company, effective December 18, 2024, after the annual meeting of stockholders. Fry brings over 35 years of investment banking experience to his new roles on the Audit and Compensation Committees. His initial compensation includes a stock option to purchase 420,000 shares of common stock. Additionally, on November 15, 2024, an amended employment agreement was executed with James Bligh, who will continue as the Interim Chief Financial Officer and Senior Vice President – Strategy. Bligh's agreement includes a £400,000 annual salary and up to a 40% discretionary cash bonus. The company also adopted an amendment to its bylaws, effective post the 2024 annual meeting, changing the quorum requirement for stockholder meetings from a majority to at least one-third of the voting power.
Conduit Pharmaceuticals Inc.宣布最近在与美国证监会的8-k表格提交中进行了重大公司变更。 2024年11月14日，在股东年会后于2024年12月18日生效，Simon Fry被任命为公司的董事。Fry将在审计和薪酬委员会上担任新职务，带来超过35年的投资银行业务经验。他的初始薪酬包括一份购买42万股普通股的期权。此外，在2024年11月15日，公司与将继续担任临时首席财务官兼首席战略副总裁的James Bligh签署了修订后的劳动协议。Bligh的协议包括40万英镑的年薪和最高40%的自由现金奖金。该公司还通过修宪，于2024年年会后生效，将股东大会的法定人数要求从多数变更为至少投票权三分之一。
Conduit Pharmaceuticals Inc.宣布最近在与美国证监会的8-k表格提交中进行了重大公司变更。 2024年11月14日，在股东年会后于2024年12月18日生效，Simon Fry被任命为公司的董事。Fry将在审计和薪酬委员会上担任新职务，带来超过35年的投资银行业务经验。他的初始薪酬包括一份购买42万股普通股的期权。此外，在2024年11月15日，公司与将继续担任临时首席财务官兼首席战略副总裁的James Bligh签署了修订后的劳动协议。Bligh的协议包括40万英镑的年薪和最高40%的自由现金奖金。该公司还通过修宪，于2024年年会后生效，将股东大会的法定人数要求从多数变更为至少投票权三分之一。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间